nodes	percent_of_prediction	percent_of_DWPC	metapath
Varenicline—CHRNB2—bronchus—esophageal cancer	0.0115	0.115	CbGeAlD
Varenicline—CHRNB2—smooth muscle tissue—esophageal cancer	0.0113	0.113	CbGeAlD
Varenicline—CHRNA7—neck—esophageal cancer	0.0109	0.109	CbGeAlD
Varenicline—CHRNB2—trachea—esophageal cancer	0.0103	0.104	CbGeAlD
Varenicline—CHRFAM7A—trachea—esophageal cancer	0.00811	0.0813	CbGeAlD
Varenicline—CHRNB2—lung—esophageal cancer	0.00743	0.0745	CbGeAlD
Varenicline—CHRNA3—lung—esophageal cancer	0.0072	0.0722	CbGeAlD
Varenicline—CHRNA4—bronchus—esophageal cancer	0.0072	0.0721	CbGeAlD
Varenicline—CHRNA7—digestive system—esophageal cancer	0.00563	0.0565	CbGeAlD
Varenicline—CHRNA4—digestive system—esophageal cancer	0.00556	0.0557	CbGeAlD
Varenicline—CHRNB2—lymph node—esophageal cancer	0.00508	0.0509	CbGeAlD
Varenicline—CHRNA3—lymph node—esophageal cancer	0.00493	0.0494	CbGeAlD
Varenicline—CHRNA4—lung—esophageal cancer	0.00464	0.0465	CbGeAlD
Varenicline—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00295	0.00327	CcSEcCtD
Varenicline—Arthritis—Capecitabine—esophageal cancer	0.00294	0.00327	CcSEcCtD
Varenicline—Pulmonary embolism—Methotrexate—esophageal cancer	0.00293	0.00326	CcSEcCtD
Varenicline—Myocardial infarction—Cisplatin—esophageal cancer	0.00293	0.00325	CcSEcCtD
Varenicline—Lethargy—Capecitabine—esophageal cancer	0.00292	0.00324	CcSEcCtD
Varenicline—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00292	0.00324	CcSEcCtD
Varenicline—Stomatitis—Cisplatin—esophageal cancer	0.00291	0.00324	CcSEcCtD
Varenicline—Conjunctivitis—Cisplatin—esophageal cancer	0.00291	0.00323	CcSEcCtD
Varenicline—Osteoarthritis—Capecitabine—esophageal cancer	0.00286	0.00318	CcSEcCtD
Varenicline—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00286	0.00318	CcSEcCtD
Varenicline—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00284	0.00315	CcSEcCtD
Varenicline—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00283	0.00314	CcSEcCtD
Varenicline—Migraine—Capecitabine—esophageal cancer	0.00281	0.00313	CcSEcCtD
Varenicline—Bradycardia—Cisplatin—esophageal cancer	0.00273	0.00303	CcSEcCtD
Varenicline—Irritability—Capecitabine—esophageal cancer	0.00273	0.00303	CcSEcCtD
Varenicline—Urinary retention—Capecitabine—esophageal cancer	0.00272	0.00302	CcSEcCtD
Varenicline—Mood swings—Capecitabine—esophageal cancer	0.00271	0.00301	CcSEcCtD
Varenicline—Mouth ulceration—Methotrexate—esophageal cancer	0.00265	0.00294	CcSEcCtD
Varenicline—Urine output increased—Methotrexate—esophageal cancer	0.00265	0.00294	CcSEcCtD
Varenicline—Urinary tract disorder—Cisplatin—esophageal cancer	0.00265	0.00294	CcSEcCtD
Varenicline—Liver function test abnormal—Capecitabine—esophageal cancer	0.00264	0.00293	CcSEcCtD
Varenicline—Connective tissue disorder—Cisplatin—esophageal cancer	0.00264	0.00293	CcSEcCtD
Varenicline—Urethral disorder—Cisplatin—esophageal cancer	0.00263	0.00292	CcSEcCtD
Varenicline—Dry skin—Capecitabine—esophageal cancer	0.00262	0.00291	CcSEcCtD
Varenicline—Abdominal pain upper—Capecitabine—esophageal cancer	0.00261	0.0029	CcSEcCtD
Varenicline—Hypokalaemia—Capecitabine—esophageal cancer	0.0026	0.00289	CcSEcCtD
Varenicline—Visual impairment—Cisplatin—esophageal cancer	0.00259	0.00287	CcSEcCtD
Varenicline—Breast disorder—Capecitabine—esophageal cancer	0.00258	0.00287	CcSEcCtD
Varenicline—Nasopharyngitis—Capecitabine—esophageal cancer	0.00256	0.00284	CcSEcCtD
Varenicline—Gastritis—Capecitabine—esophageal cancer	0.00253	0.00281	CcSEcCtD
Varenicline—Eye disorder—Cisplatin—esophageal cancer	0.00251	0.00279	CcSEcCtD
Varenicline—Tinnitus—Cisplatin—esophageal cancer	0.0025	0.00278	CcSEcCtD
Varenicline—Lymphadenopathy—Methotrexate—esophageal cancer	0.00249	0.00277	CcSEcCtD
Varenicline—Cardiac disorder—Cisplatin—esophageal cancer	0.00249	0.00277	CcSEcCtD
Varenicline—Abdominal distension—Capecitabine—esophageal cancer	0.00249	0.00276	CcSEcCtD
Varenicline—Asthma—Capecitabine—esophageal cancer	0.00247	0.00274	CcSEcCtD
Varenicline—Dysphagia—Capecitabine—esophageal cancer	0.00247	0.00274	CcSEcCtD
Varenicline—Diabetes mellitus—Methotrexate—esophageal cancer	0.00245	0.00272	CcSEcCtD
Varenicline—Polyuria—Methotrexate—esophageal cancer	0.00242	0.00269	CcSEcCtD
Varenicline—Immune system disorder—Cisplatin—esophageal cancer	0.00242	0.00269	CcSEcCtD
Varenicline—Mediastinal disorder—Cisplatin—esophageal cancer	0.00242	0.00269	CcSEcCtD
Varenicline—Angina pectoris—Capecitabine—esophageal cancer	0.00241	0.00267	CcSEcCtD
Varenicline—Arrhythmia—Cisplatin—esophageal cancer	0.0024	0.00266	CcSEcCtD
Varenicline—Bronchitis—Capecitabine—esophageal cancer	0.00238	0.00264	CcSEcCtD
Varenicline—Abdominal discomfort—Capecitabine—esophageal cancer	0.00237	0.00263	CcSEcCtD
Varenicline—Erythema—Cisplatin—esophageal cancer	0.00234	0.00259	CcSEcCtD
Varenicline—Malnutrition—Cisplatin—esophageal cancer	0.00234	0.00259	CcSEcCtD
Varenicline—Renal failure acute—Methotrexate—esophageal cancer	0.00231	0.00256	CcSEcCtD
Varenicline—Flatulence—Cisplatin—esophageal cancer	0.0023	0.00256	CcSEcCtD
Varenicline—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00226	0.00251	CcSEcCtD
Varenicline—Weight increased—Capecitabine—esophageal cancer	0.00225	0.0025	CcSEcCtD
Varenicline—Visual disturbance—Methotrexate—esophageal cancer	0.00225	0.00249	CcSEcCtD
Varenicline—Muscle spasms—Cisplatin—esophageal cancer	0.00225	0.00249	CcSEcCtD
Varenicline—Hyperglycaemia—Capecitabine—esophageal cancer	0.00223	0.00248	CcSEcCtD
Varenicline—Infestation NOS—Capecitabine—esophageal cancer	0.0022	0.00245	CcSEcCtD
Varenicline—Infestation—Capecitabine—esophageal cancer	0.0022	0.00245	CcSEcCtD
Varenicline—Vision blurred—Cisplatin—esophageal cancer	0.0022	0.00245	CcSEcCtD
Varenicline—Depression—Capecitabine—esophageal cancer	0.0022	0.00244	CcSEcCtD
Varenicline—Tremor—Cisplatin—esophageal cancer	0.00219	0.00243	CcSEcCtD
Varenicline—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00218	0.00243	CcSEcCtD
Varenicline—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00217	0.00241	CcSEcCtD
Varenicline—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00217	0.00241	CcSEcCtD
Varenicline—Lethargy—Methotrexate—esophageal cancer	0.00217	0.00241	CcSEcCtD
Varenicline—Ill-defined disorder—Cisplatin—esophageal cancer	0.00217	0.00241	CcSEcCtD
Varenicline—Myocardial infarction—Capecitabine—esophageal cancer	0.00216	0.0024	CcSEcCtD
Varenicline—Anaemia—Cisplatin—esophageal cancer	0.00216	0.0024	CcSEcCtD
Varenicline—Stomatitis—Capecitabine—esophageal cancer	0.00215	0.00239	CcSEcCtD
Varenicline—Conjunctivitis—Capecitabine—esophageal cancer	0.00214	0.00238	CcSEcCtD
Varenicline—Osteoarthritis—Methotrexate—esophageal cancer	0.00213	0.00236	CcSEcCtD
Varenicline—Malaise—Cisplatin—esophageal cancer	0.00211	0.00234	CcSEcCtD
Varenicline—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00208	0.00231	CcSEcCtD
Varenicline—Epistaxis—Capecitabine—esophageal cancer	0.00208	0.00231	CcSEcCtD
Varenicline—Irritability—Methotrexate—esophageal cancer	0.00203	0.00226	CcSEcCtD
Varenicline—Convulsion—Cisplatin—esophageal cancer	0.00202	0.00225	CcSEcCtD
Varenicline—Mood swings—Methotrexate—esophageal cancer	0.00202	0.00224	CcSEcCtD
Varenicline—Bradycardia—Capecitabine—esophageal cancer	0.00201	0.00224	CcSEcCtD
Varenicline—Myalgia—Cisplatin—esophageal cancer	0.00199	0.00221	CcSEcCtD
Varenicline—Anxiety—Cisplatin—esophageal cancer	0.00198	0.0022	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00197	0.00219	CcSEcCtD
Varenicline—Hypoaesthesia—Capecitabine—esophageal cancer	0.00197	0.00219	CcSEcCtD
Varenicline—Liver function test abnormal—Methotrexate—esophageal cancer	0.00196	0.00218	CcSEcCtD
Varenicline—Discomfort—Cisplatin—esophageal cancer	0.00196	0.00218	CcSEcCtD
Varenicline—Urinary tract disorder—Capecitabine—esophageal cancer	0.00195	0.00217	CcSEcCtD
Varenicline—Oedema peripheral—Capecitabine—esophageal cancer	0.00195	0.00216	CcSEcCtD
Varenicline—Connective tissue disorder—Capecitabine—esophageal cancer	0.00194	0.00216	CcSEcCtD
Varenicline—Urethral disorder—Capecitabine—esophageal cancer	0.00194	0.00215	CcSEcCtD
Varenicline—Breast disorder—Methotrexate—esophageal cancer	0.00192	0.00214	CcSEcCtD
Varenicline—Oedema—Cisplatin—esophageal cancer	0.00191	0.00212	CcSEcCtD
Varenicline—Visual impairment—Capecitabine—esophageal cancer	0.00191	0.00212	CcSEcCtD
Varenicline—Infection—Cisplatin—esophageal cancer	0.00189	0.0021	CcSEcCtD
Varenicline—Erythema multiforme—Capecitabine—esophageal cancer	0.00187	0.00208	CcSEcCtD
Varenicline—Nervous system disorder—Cisplatin—esophageal cancer	0.00187	0.00208	CcSEcCtD
Varenicline—Thrombocytopenia—Cisplatin—esophageal cancer	0.00187	0.00207	CcSEcCtD
Varenicline—Tachycardia—Cisplatin—esophageal cancer	0.00186	0.00207	CcSEcCtD
Varenicline—Skin disorder—Cisplatin—esophageal cancer	0.00185	0.00206	CcSEcCtD
Varenicline—Eye disorder—Capecitabine—esophageal cancer	0.00185	0.00205	CcSEcCtD
Varenicline—Tinnitus—Capecitabine—esophageal cancer	0.00184	0.00205	CcSEcCtD
Varenicline—Hyperhidrosis—Cisplatin—esophageal cancer	0.00184	0.00205	CcSEcCtD
Varenicline—Asthma—Methotrexate—esophageal cancer	0.00184	0.00204	CcSEcCtD
Varenicline—Cardiac disorder—Capecitabine—esophageal cancer	0.00184	0.00204	CcSEcCtD
Varenicline—Anorexia—Cisplatin—esophageal cancer	0.00182	0.00202	CcSEcCtD
Varenicline—Angiopathy—Capecitabine—esophageal cancer	0.00179	0.00199	CcSEcCtD
Varenicline—Immune system disorder—Capecitabine—esophageal cancer	0.00179	0.00198	CcSEcCtD
Varenicline—Mediastinal disorder—Capecitabine—esophageal cancer	0.00178	0.00198	CcSEcCtD
Varenicline—Hypotension—Cisplatin—esophageal cancer	0.00178	0.00198	CcSEcCtD
Varenicline—Chills—Capecitabine—esophageal cancer	0.00177	0.00197	CcSEcCtD
Varenicline—Arrhythmia—Capecitabine—esophageal cancer	0.00177	0.00196	CcSEcCtD
Varenicline—Abdominal discomfort—Methotrexate—esophageal cancer	0.00176	0.00196	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00174	0.00193	CcSEcCtD
Varenicline—Mental disorder—Capecitabine—esophageal cancer	0.00173	0.00192	CcSEcCtD
Varenicline—Malnutrition—Capecitabine—esophageal cancer	0.00172	0.00191	CcSEcCtD
Varenicline—Erythema—Capecitabine—esophageal cancer	0.00172	0.00191	CcSEcCtD
Varenicline—Dyspnoea—Cisplatin—esophageal cancer	0.0017	0.00189	CcSEcCtD
Varenicline—Flatulence—Capecitabine—esophageal cancer	0.0017	0.00188	CcSEcCtD
Varenicline—Erectile dysfunction—Methotrexate—esophageal cancer	0.00169	0.00188	CcSEcCtD
Varenicline—Dysgeusia—Capecitabine—esophageal cancer	0.00169	0.00187	CcSEcCtD
Varenicline—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00168	0.00186	CcSEcCtD
Varenicline—Back pain—Capecitabine—esophageal cancer	0.00167	0.00185	CcSEcCtD
Varenicline—Decreased appetite—Cisplatin—esophageal cancer	0.00166	0.00184	CcSEcCtD
Varenicline—Muscle spasms—Capecitabine—esophageal cancer	0.00166	0.00184	CcSEcCtD
Varenicline—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00165	0.00183	CcSEcCtD
Varenicline—Infestation—Methotrexate—esophageal cancer	0.00164	0.00182	CcSEcCtD
Varenicline—Infestation NOS—Methotrexate—esophageal cancer	0.00164	0.00182	CcSEcCtD
Varenicline—Depression—Methotrexate—esophageal cancer	0.00164	0.00182	CcSEcCtD
Varenicline—Pain—Cisplatin—esophageal cancer	0.00163	0.00181	CcSEcCtD
Varenicline—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00163	0.00181	CcSEcCtD
Varenicline—Vision blurred—Capecitabine—esophageal cancer	0.00162	0.0018	CcSEcCtD
Varenicline—Tremor—Capecitabine—esophageal cancer	0.00161	0.00179	CcSEcCtD
Varenicline—Stomatitis—Methotrexate—esophageal cancer	0.0016	0.00178	CcSEcCtD
Varenicline—Ill-defined disorder—Capecitabine—esophageal cancer	0.0016	0.00177	CcSEcCtD
Varenicline—Conjunctivitis—Methotrexate—esophageal cancer	0.00159	0.00177	CcSEcCtD
Varenicline—Anaemia—Capecitabine—esophageal cancer	0.00159	0.00177	CcSEcCtD
Varenicline—Feeling abnormal—Cisplatin—esophageal cancer	0.00157	0.00174	CcSEcCtD
Varenicline—Malaise—Capecitabine—esophageal cancer	0.00155	0.00172	CcSEcCtD
Varenicline—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00155	0.00172	CcSEcCtD
Varenicline—Epistaxis—Methotrexate—esophageal cancer	0.00155	0.00172	CcSEcCtD
Varenicline—Vertigo—Capecitabine—esophageal cancer	0.00155	0.00172	CcSEcCtD
Varenicline—Syncope—Capecitabine—esophageal cancer	0.00154	0.00172	CcSEcCtD
Varenicline—Palpitations—Capecitabine—esophageal cancer	0.00152	0.00169	CcSEcCtD
Varenicline—Loss of consciousness—Capecitabine—esophageal cancer	0.00151	0.00168	CcSEcCtD
Varenicline—Body temperature increased—Cisplatin—esophageal cancer	0.00151	0.00167	CcSEcCtD
Varenicline—Cough—Capecitabine—esophageal cancer	0.0015	0.00167	CcSEcCtD
Varenicline—Hypertension—Capecitabine—esophageal cancer	0.00149	0.00165	CcSEcCtD
Varenicline—Arthralgia—Capecitabine—esophageal cancer	0.00147	0.00163	CcSEcCtD
Varenicline—Chest pain—Capecitabine—esophageal cancer	0.00147	0.00163	CcSEcCtD
Varenicline—Myalgia—Capecitabine—esophageal cancer	0.00147	0.00163	CcSEcCtD
Varenicline—Anxiety—Capecitabine—esophageal cancer	0.00146	0.00162	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00146	0.00162	CcSEcCtD
Varenicline—Urinary tract disorder—Methotrexate—esophageal cancer	0.00145	0.00162	CcSEcCtD
Varenicline—Discomfort—Capecitabine—esophageal cancer	0.00145	0.00161	CcSEcCtD
Varenicline—Urethral disorder—Methotrexate—esophageal cancer	0.00144	0.0016	CcSEcCtD
Varenicline—Dry mouth—Capecitabine—esophageal cancer	0.00143	0.00159	CcSEcCtD
Varenicline—Visual impairment—Methotrexate—esophageal cancer	0.00142	0.00158	CcSEcCtD
Varenicline—Oedema—Capecitabine—esophageal cancer	0.00141	0.00156	CcSEcCtD
Varenicline—Hypersensitivity—Cisplatin—esophageal cancer	0.0014	0.00156	CcSEcCtD
Varenicline—Infection—Capecitabine—esophageal cancer	0.0014	0.00155	CcSEcCtD
Varenicline—Erythema multiforme—Methotrexate—esophageal cancer	0.00139	0.00155	CcSEcCtD
Varenicline—Shock—Capecitabine—esophageal cancer	0.00138	0.00154	CcSEcCtD
Varenicline—Nervous system disorder—Capecitabine—esophageal cancer	0.00138	0.00153	CcSEcCtD
Varenicline—Eye disorder—Methotrexate—esophageal cancer	0.00138	0.00153	CcSEcCtD
Varenicline—Thrombocytopenia—Capecitabine—esophageal cancer	0.00138	0.00153	CcSEcCtD
Varenicline—Tinnitus—Methotrexate—esophageal cancer	0.00137	0.00152	CcSEcCtD
Varenicline—Tachycardia—Capecitabine—esophageal cancer	0.00137	0.00152	CcSEcCtD
Varenicline—Asthenia—Cisplatin—esophageal cancer	0.00137	0.00152	CcSEcCtD
Varenicline—Cardiac disorder—Methotrexate—esophageal cancer	0.00137	0.00152	CcSEcCtD
Varenicline—Skin disorder—Capecitabine—esophageal cancer	0.00136	0.00152	CcSEcCtD
Varenicline—Hyperhidrosis—Capecitabine—esophageal cancer	0.00136	0.00151	CcSEcCtD
Varenicline—Anorexia—Capecitabine—esophageal cancer	0.00134	0.00149	CcSEcCtD
Varenicline—Angiopathy—Methotrexate—esophageal cancer	0.00134	0.00148	CcSEcCtD
Varenicline—Immune system disorder—Methotrexate—esophageal cancer	0.00133	0.00148	CcSEcCtD
Varenicline—Mediastinal disorder—Methotrexate—esophageal cancer	0.00133	0.00147	CcSEcCtD
Varenicline—Chills—Methotrexate—esophageal cancer	0.00132	0.00147	CcSEcCtD
Varenicline—Hypotension—Capecitabine—esophageal cancer	0.00131	0.00146	CcSEcCtD
Varenicline—Diarrhoea—Cisplatin—esophageal cancer	0.0013	0.00145	CcSEcCtD
Varenicline—Mental disorder—Methotrexate—esophageal cancer	0.00129	0.00143	CcSEcCtD
Varenicline—Erythema—Methotrexate—esophageal cancer	0.00128	0.00142	CcSEcCtD
Varenicline—Malnutrition—Methotrexate—esophageal cancer	0.00128	0.00142	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00128	0.00142	CcSEcCtD
Varenicline—Insomnia—Capecitabine—esophageal cancer	0.00127	0.00141	CcSEcCtD
Varenicline—Dysgeusia—Methotrexate—esophageal cancer	0.00126	0.00139	CcSEcCtD
Varenicline—Dyspnoea—Capecitabine—esophageal cancer	0.00125	0.00139	CcSEcCtD
Varenicline—Back pain—Methotrexate—esophageal cancer	0.00124	0.00138	CcSEcCtD
Varenicline—Dyspepsia—Capecitabine—esophageal cancer	0.00124	0.00137	CcSEcCtD
Varenicline—Decreased appetite—Capecitabine—esophageal cancer	0.00122	0.00136	CcSEcCtD
Varenicline—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00121	0.00135	CcSEcCtD
Varenicline—Vomiting—Cisplatin—esophageal cancer	0.00121	0.00135	CcSEcCtD
Varenicline—Fatigue—Capecitabine—esophageal cancer	0.00121	0.00135	CcSEcCtD
Varenicline—Vision blurred—Methotrexate—esophageal cancer	0.00121	0.00134	CcSEcCtD
Varenicline—Rash—Cisplatin—esophageal cancer	0.0012	0.00134	CcSEcCtD
Varenicline—Constipation—Capecitabine—esophageal cancer	0.0012	0.00133	CcSEcCtD
Varenicline—Pain—Capecitabine—esophageal cancer	0.0012	0.00133	CcSEcCtD
Varenicline—Dermatitis—Cisplatin—esophageal cancer	0.0012	0.00133	CcSEcCtD
Varenicline—Ill-defined disorder—Methotrexate—esophageal cancer	0.00119	0.00132	CcSEcCtD
Varenicline—Anaemia—Methotrexate—esophageal cancer	0.00118	0.00132	CcSEcCtD
Varenicline—Feeling abnormal—Capecitabine—esophageal cancer	0.00116	0.00129	CcSEcCtD
Varenicline—Malaise—Methotrexate—esophageal cancer	0.00116	0.00128	CcSEcCtD
Varenicline—Vertigo—Methotrexate—esophageal cancer	0.00115	0.00128	CcSEcCtD
Varenicline—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00115	0.00128	CcSEcCtD
Varenicline—Nausea—Cisplatin—esophageal cancer	0.00113	0.00126	CcSEcCtD
Varenicline—Cough—Methotrexate—esophageal cancer	0.00112	0.00124	CcSEcCtD
Varenicline—Urticaria—Capecitabine—esophageal cancer	0.00112	0.00124	CcSEcCtD
Varenicline—Abdominal pain—Capecitabine—esophageal cancer	0.00111	0.00123	CcSEcCtD
Varenicline—Body temperature increased—Capecitabine—esophageal cancer	0.00111	0.00123	CcSEcCtD
Varenicline—Convulsion—Methotrexate—esophageal cancer	0.00111	0.00123	CcSEcCtD
Varenicline—Chest pain—Methotrexate—esophageal cancer	0.00109	0.00121	CcSEcCtD
Varenicline—Myalgia—Methotrexate—esophageal cancer	0.00109	0.00121	CcSEcCtD
Varenicline—Arthralgia—Methotrexate—esophageal cancer	0.00109	0.00121	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00108	0.0012	CcSEcCtD
Varenicline—Discomfort—Methotrexate—esophageal cancer	0.00108	0.0012	CcSEcCtD
Varenicline—Infection—Methotrexate—esophageal cancer	0.00104	0.00115	CcSEcCtD
Varenicline—Hypersensitivity—Capecitabine—esophageal cancer	0.00104	0.00115	CcSEcCtD
Varenicline—Nervous system disorder—Methotrexate—esophageal cancer	0.00103	0.00114	CcSEcCtD
Varenicline—Thrombocytopenia—Methotrexate—esophageal cancer	0.00102	0.00114	CcSEcCtD
Varenicline—Skin disorder—Methotrexate—esophageal cancer	0.00102	0.00113	CcSEcCtD
Varenicline—Hyperhidrosis—Methotrexate—esophageal cancer	0.00101	0.00112	CcSEcCtD
Varenicline—Asthenia—Capecitabine—esophageal cancer	0.00101	0.00112	CcSEcCtD
Varenicline—Anorexia—Methotrexate—esophageal cancer	0.000997	0.00111	CcSEcCtD
Varenicline—Pruritus—Capecitabine—esophageal cancer	0.000994	0.0011	CcSEcCtD
Varenicline—Hypotension—Methotrexate—esophageal cancer	0.000977	0.00109	CcSEcCtD
Varenicline—Diarrhoea—Capecitabine—esophageal cancer	0.000961	0.00107	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000953	0.00106	CcSEcCtD
Varenicline—Insomnia—Methotrexate—esophageal cancer	0.000946	0.00105	CcSEcCtD
Varenicline—Dyspnoea—Methotrexate—esophageal cancer	0.000933	0.00104	CcSEcCtD
Varenicline—Somnolence—Methotrexate—esophageal cancer	0.00093	0.00103	CcSEcCtD
Varenicline—Dizziness—Capecitabine—esophageal cancer	0.000929	0.00103	CcSEcCtD
Varenicline—Dyspepsia—Methotrexate—esophageal cancer	0.000921	0.00102	CcSEcCtD
Varenicline—Decreased appetite—Methotrexate—esophageal cancer	0.000909	0.00101	CcSEcCtD
Varenicline—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000903	0.001	CcSEcCtD
Varenicline—Fatigue—Methotrexate—esophageal cancer	0.000902	0.001	CcSEcCtD
Varenicline—Pain—Methotrexate—esophageal cancer	0.000894	0.000994	CcSEcCtD
Varenicline—Vomiting—Capecitabine—esophageal cancer	0.000893	0.000992	CcSEcCtD
Varenicline—Rash—Capecitabine—esophageal cancer	0.000886	0.000984	CcSEcCtD
Varenicline—Dermatitis—Capecitabine—esophageal cancer	0.000885	0.000983	CcSEcCtD
Varenicline—Headache—Capecitabine—esophageal cancer	0.00088	0.000978	CcSEcCtD
Varenicline—Feeling abnormal—Methotrexate—esophageal cancer	0.000862	0.000957	CcSEcCtD
Varenicline—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000855	0.00095	CcSEcCtD
Varenicline—Nausea—Capecitabine—esophageal cancer	0.000835	0.000927	CcSEcCtD
Varenicline—Urticaria—Methotrexate—esophageal cancer	0.000831	0.000923	CcSEcCtD
Varenicline—Body temperature increased—Methotrexate—esophageal cancer	0.000827	0.000919	CcSEcCtD
Varenicline—Abdominal pain—Methotrexate—esophageal cancer	0.000827	0.000919	CcSEcCtD
Varenicline—Hypersensitivity—Methotrexate—esophageal cancer	0.000771	0.000856	CcSEcCtD
Varenicline—Asthenia—Methotrexate—esophageal cancer	0.00075	0.000834	CcSEcCtD
Varenicline—Pruritus—Methotrexate—esophageal cancer	0.00074	0.000822	CcSEcCtD
Varenicline—Diarrhoea—Methotrexate—esophageal cancer	0.000716	0.000795	CcSEcCtD
Varenicline—Dizziness—Methotrexate—esophageal cancer	0.000692	0.000768	CcSEcCtD
Varenicline—Vomiting—Methotrexate—esophageal cancer	0.000665	0.000739	CcSEcCtD
Varenicline—Rash—Methotrexate—esophageal cancer	0.00066	0.000733	CcSEcCtD
Varenicline—Dermatitis—Methotrexate—esophageal cancer	0.000659	0.000732	CcSEcCtD
Varenicline—Headache—Methotrexate—esophageal cancer	0.000655	0.000728	CcSEcCtD
Varenicline—Nausea—Methotrexate—esophageal cancer	0.000621	0.00069	CcSEcCtD
